← Back to Search

Non-invasive Brain Stimulation

rTMS for Depression

N/A
Recruiting
Led By Nolan Williams, MD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Male or Female, between the ages of 22 and 65 at the time of screening
Male or Female, between the ages of 22 and 65 at the time of screening.
Must not have
Depth-adjusted aiTBS treatment dose > 65% maximum stimulator output (MSO)
Untreated or insufficiently treated endocrine disorder
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline (pre-intervention), during the intervention and immediately after the intervention.

Summary

This trial looks at whether a new kind of brain stimulation called "aiTBS" can help people with borderline personality disorder who also have depression.

Who is the study for?
Adults aged 22-65 with Borderline Personality Disorder and a current depressive episode, who are in good health, TMS naive, agree to lifestyle guidelines, use effective contraception if applicable, can understand English for assessments/interventions. Excludes pregnant individuals or those with mania/psychosis, substance abuse issues, certain medical conditions like metal implants incompatible with MRI or history of seizures.
What is being tested?
The trial tests an accelerated form of theta-burst stimulation (aiTBS) on the brain's left dorsolateral prefrontal cortex and dorsomedial prefrontal cortex versus sham stimulation. It aims to assess aiTBS's effectiveness in alleviating depression symptoms in participants with BPD during a depressive episode.
What are the potential side effects?
Potential side effects may include discomfort at the stimulation site, headache, lightheadedness, temporary hearing changes due to the noise of the machine. Rarely there could be seizure risk or more severe headaches.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 22 and 65 years old.
Select...
I am between 22 and 65 years old.
Select...
I have been diagnosed with MDD, BAPD II, or unspecified depressive disorder and Borderline Personality Disorder.
Select...
I have never undergone TMS therapy.
Select...
I have never undergone TMS therapy.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My treatment's intensity is more than 65% of the maximum level.
Select...
I have a hormone disorder that hasn't been treated enough.
Select...
I have used ketamine or had ECT for depression recently.
Select...
I am currently experiencing mania or psychosis.
Select...
I have a history of serious brain or nerve conditions.
Select...
I've had more than 8 ECT sessions without improvement.
Select...
I have been diagnosed with obsessive-compulsive disorder.
Select...
I do not have metal implants in my head, a history of seizures, or known brain lesions.
Select...
I have been diagnosed with Bipolar I Disorder or a primary psychotic disorder.
Select...
I sleep at least 5 hours each night.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at baseline (pre-intervention), during the intervention and immediately after the intervention.
This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline (pre-intervention), during the intervention and immediately after the intervention. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mental Depression
Secondary study objectives
Change in the clinician rated Montgomery-Asberg Depression Rating Scale (MADRS-C) in active DMPFC vs. sham aiTBS.
Feasibility of aiTBS in individuals with BPD and comorbid MDD or BAD II in a current MDE as defined by recruitment rate
Feasibility of aiTBS in individuals with BPD and comorbid MDD or BAD II in a current MDE as defined by retention rates
+1 more

Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: Left Dorsolateral Prefrontal Cortex (L-DLPFC)Active Control1 Intervention
The accelerated theta burst stimulation protocol will be applied to the left dorsolateral prefrontal cortex (L-DLPFC)
Group II: Dorsomedial Prefrontal Cortex (DMPFC)Active Control1 Intervention
The accelerated theta burst stimulation protocol will be applied to the dorsomedial prefrontal cortex (DMPFC)
Group III: Sham stimulationPlacebo Group1 Intervention
Sham (non-active) stimulation will be applied to the left dorsolateral prefrontal cortex (DLPFC) region

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,474 Previous Clinical Trials
17,501,895 Total Patients Enrolled
2 Trials studying Borderline Personality Disorder
63 Patients Enrolled for Borderline Personality Disorder
Nolan Williams, MDPrincipal InvestigatorStanford University
17 Previous Clinical Trials
1,237 Total Patients Enrolled
David Spiegel, MDPrincipal InvestigatorStanford University
11 Previous Clinical Trials
1,772 Total Patients Enrolled

Media Library

Dorsomedial Prefrontal Cortex (DMPFC) (Non-invasive Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT04870255 — N/A
Borderline Personality Disorder Research Study Groups: Left Dorsolateral Prefrontal Cortex (L-DLPFC), Dorsomedial Prefrontal Cortex (DMPFC), Sham stimulation
Borderline Personality Disorder Clinical Trial 2023: Dorsomedial Prefrontal Cortex (DMPFC) Highlights & Side Effects. Trial Name: NCT04870255 — N/A
Dorsomedial Prefrontal Cortex (DMPFC) (Non-invasive Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04870255 — N/A
Borderline Personality Disorder Patient Testimony for trial: Trial Name: NCT04870255 — N/A
~10 spots leftby Nov 2025